Clinical Efficacy and Safety of Osimertinib in the Treatment of EGFR Gene Mutation-Positive NSCLC Patients in the Real World

TU Wenlian; DONG Lanlan; MIN Qiuxia; CAO Wei

doi:10.14009/j.issn.1672-2124.2022.09.010

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy and Safety of Osimertinib in the Treatment of EGFR Gene Mutation-Positive NSCLC Patients in the Real World

更新时间：2023-04-16

- Clinical Efficacy and Safety of Osimertinib in the Treatment of EGFR Gene Mutation-Positive NSCLC Patients in the Real World
- Vol. 22, Issue 9, Pages: 1068-1071(2022)
- 作者机构：
  
  1. 云南省第一人民医院药学部/昆明理工大学附属昆华医院药学部
  2. 大理大学药学院
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.09.010
  CLC： R734.2
- Published：2022，
扫描看全文
TU Wenlian, DONG Lanlan, MIN Qiuxia, et al. Clinical Efficacy and Safety of Osimertinib in the Treatment of EGFR Gene Mutation-Positive NSCLC Patients in the Real World. [J]. 22(9):1068-1071(2022)
DOI：

TU Wenlian, DONG Lanlan, MIN Qiuxia, et al. Clinical Efficacy and Safety of Osimertinib in the Treatment of EGFR Gene Mutation-Positive NSCLC Patients in the Real World. [J]. 22(9):1068-1071(2022) DOI： 10.14009/j.issn.1672-2124.2022.09.010.

摘要

目的：探讨奥希替尼在真实世界中治疗表皮生长因子受体(EGFR)基因突变阳性的非小细胞肺癌(NSCLC)患者的临床疗效及安全性。方法：选取2019年1月至2021年3月云南省第一人民医院收治的具有EGFR基因突变且使用奥希替尼治疗的NSCLC患者52例作为研究对象，评价奥希替尼的疗效及安全性。结果：52例患者中，总体疾病控制率为90.4%(47/52)

中位无进展生存期为12.0个月(95%CI:8.2～15.8个月)

中位总生存期为21.0个月(95%CI:13.0～28.9个月)。患者的不良反应主要表现为腹泻(发生率为44.2%

23/52)、皮肤干燥(发生率为25.0%

13/52)、皮疹(发生率为23.1%

12/52)、甲沟炎(发生率为21.2%

11/52)和恶心呕吐(发生率为21.2%

11/52)等；3度及以上不良反应发生率为15.4%(8/52)。结论：在真实世界中，奥希替尼对EGFR突变阳性的NSCLC患者临床治疗效果确切，且安全性良好。

Abstract

OBJECTIVE: To explore the clinical efficacy and safety of osimertinib in the treatment of epidermal growth factor receptor（EGFR） gene mutation-positive non-small cell lung cancer（NSCLC） patients in the real world. METHODS: A total of 52 NSCLC patients with EGFR gene mutation treated with osimertinib in the First People’s Hospital of Yunnan from Jan. 2019 to Mar. 2021 were extracted as the research objects

the efficacy and safety of osimertinib were evaluated. RESULTS: Among the 52 patients

the overall disease control rate was 90.4%（47/52）

the median progression-free survival was 12.0 months（95%CI: from 8.2 to 15.8 months）

and the median overall survival was 21.0 months（95%CI: from 13.0 to 28.9 months）. The main adverse drug reactions were diarrhea（44.2%

23/52）

dry skin（25.0%

13/52）

rash（23.1%

12/52）

paronychia（21.2%

11/52） and nausea and vomiting（21.2%

11/52）. The incidence of adverse drug reactions of grade Ⅲ and above was 15.4%（8/52）. CONCLUSIONS: In the real world

the efficacy of osimertinib in the treatment of EGFR gene mutation-positive NSCLC patients is significant

with higher safety.

关键词

奥希替尼临床疗效不良反应表皮生长因子受体非小细胞肺癌

Keywords

OsimertinibClinical efficacyAdverse drug reactionsEpidermal growth factor receptorNon-small cell lung cancer

references

查看原文

Views

116

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Retrospective Study on Economy and Efficacy of Osimertinib in Posterior-line Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

Systematic Review of Huisheng Oral Liquid on Coagulation Function, Efficacy and Safety of Patients with Non-Small Cell Lung Cancer

Huanshao Capsules Combined with Tamsulosin Hydrochloride in the Treatment of Premature Ejaculation of Spleen and Kidney Yang Deficiency Type

Effects of Fiberoptic Bronchoalveolar Lavage Combined with Azithromycin on Immune Function, Serum MCP-4, MAPK and CysLTR1 in Children with Mycoplasma Pneumoniae Pneumonia

Prognosis and Safety of Programmed Death 1 Inhibitors in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Related Author

HE Tingting

WANG Yubo

FU Ming

ZHANG Jinhua

TIAN Yuan

YANG Xiaoping

ZHANG Yi

DOU Jianguo

Related Institution

Dept. of Respiratory and Critical Care Medicine,Army Medical Center of PLA

Dept. of Internal Medicine of Traditional Chinese Medicine, Shanghai Tongren Hospital

Dept. of Internal Medicine of Traditional Chinese Medicine, Shanghai Seventh People’s Hospital

Traditional Chinese Medicine Phenomics Research Center, Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University

Dept. of Oncology, Jingmen First People’s Hospital

⁰